Among 87 enrolled patients, 22 had luminal A breast cancer, 24 had luminal B breast cancer, 13 had HER‐2‐positive breast cancer, and 28 had triple‐negative breast cancer (TNBC). Here, ERBB2 is linked to breast carcinoma.